compounded glp 1 providers GLP-1 Weight Loss Treatment Amanda Bonello interviews Sabina Hemmi,

The boring, slow, expensive infrastructure of behavioral neuroscience

Were giving you an in-depth look at all of the 2025 prescription drug trends and where we see things going in the future, including non-specialty medications

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

In the past seven years, the proportion of new, commercial patients who are rejected for a launch brand increased from 37% to 56%, such that more than half of the attempts to initiate a new treatment in 2022 were unfilled the first year

Wegovy now $199

MedTech stocks continue to feel pressure from glucagon-like peptide-1 (GLP-1) drugs for obesity, based primarily on speculation, and despite strong third-quarter performances from many firms in this sector